Health Care & Life Sciences » Biotechnology | Matinas BioPharma Holdings Inc.

Matinas BioPharma Holdings Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2014
2015
2016
2017
2018
Sales/Revenue
-
194.50
-
149.70
119.80
Cost of Goods Sold (COGS) incl. D&A
41.60
-
52.60
-
-
Gross Income
41.60
-
52.60
-
-
SG&A Expense
10,423.40
9,209.10
8,204.50
16,551.50
14,548
EBIT
10,465.00
9,058.20
8,257.10
16,502.40
14,646.50
Unusual Expense
269.10
96.90
674.90
636.90
-
Non Operating Income/Expense
25.20
20.50
-
22.00
56.60
Interest Expense
-
0.90
16.50
-
-
Pretax Income
10,221.00
9,135.40
7,598.70
15,843.40
14,590
Income Tax
-
-
-
357.00
506.90
Consolidated Net Income
10,221.00
9,135.40
7,598.70
32,227.80
14,083.10
Net Income
10,221.00
9,135.40
7,598.70
32,227.80
14,083.10
Net Income After Extraordinaries
10,221.00
9,135.40
7,598.70
32,227.80
14,083.10
Net Income Available to Common
10,221.00
9,135.40
11,992.50
32,836.20
14,988.10
EPS (Basic)
0.32
0.18
0.21
0.36
0.15
Basic Shares Outstanding
32,076.70
51,481.00
57,654.80
90,475.00
98,103.20
EPS (Diluted)
0.32
0.18
0.21
0.36
0.15
Diluted Shares Outstanding
32,076.70
51,481.00
57,654.80
90,475.00
98,103.20
EBITDA
10,423.40
9,014.70
8,204.50
16,401.80
14,428.20
Other After Tax Income (Expense)
-
-
-
16,741.40
-
Preferred Dividends
-
-
4,393.80
608.30
905

About Matinas BioPharma Holdings

View Profile
Address
1545 Route 206 South
Bedminster New Jersey 07921
United States
Employees -
Website http://www.matinasbiopharma.com
Updated 07/08/2019
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its LNC platform technology. The company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Its lead anti-fungal product candidate, MAT2203, delivers broad-spectrum fungicidal agent, amphotericin B; and is being developed to prevent invasive fungal infections in patients with acute lymphoblastic leukemia.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.